InterCure Holdings (Canndoc)

www.intercure.co ; www.canndoc.com

Holding Company
Public Company

(NASDAQ GM: INCR), (TASE: INCR)

Tech Verticals Preferences

Biomed, Digital Health, Medical Cannabis, Medical Devices

General Data

Established	2015
Current Active Portfolio Companies:	1
Reg. Number:	abCDe

DESCRIPTION

InterCure (dba Canndoc) is a Life Science Holding Company. It is the first public company on the Tel Aviv Stock Exchange to hold a valid and permanent license for the medical cannabis value chain through its 100% ownership in Canndoc. Canndoc is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.

AFFILIATION

Account ID	Affiliation Type	Name	Parent Name	Status
2D1F341A-207A-E111-AC59-00155D32A403		XTL Biopharmaceuticals Ltd.
09C967EA-1F7A-E111-AC59-00155D32A403	Subsidiary	InterCure Ltd.	XTL Biopharmaceuticals Ltd.	Acquired/Merged
23D07916-1C79-E811-80E9-00155D0B832C	Spin-off	InterCure Holdings (Canndoc)	InterCure Ltd.
	Subsidiary	Canndoc Ltd.	InterCure Holdings (Canndoc)	Acquired/Merged

REMARKS

Date	Remark
28/08/2024	InterCure announced a new strategic agreement with Cookies, the globally recognized cannabis brand, to cultivate, manufacture, import and distribute Cookies’ branded products, produced from its cultivation and manufacturing facilities in 8 licensed branded pharmacies across Germany, through Cookies Corners.
09/12/2018	Intercure used to be a High Tech company with tech of its own - It was sold to Alexander Rabinovich and changed into a Holding Company investing in Biomed, Biotechnology and Medical Devices in 02/2015. During 2018-2019 Intecure has purchased Medical Cannabis company Canndoc, which became its main activity.

CONTACT INFO

Expand / Collapse All

Main Address: Herzliya, Israel

Address	85 Medinat Hayehudim
City	Herzliya
Country	Israel
Zip	4676670

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title
Mr. Alexander Rabinovich	CEO
Mr. Amos Cohen	CFO

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	CEO , InterCure Holdings
abC Defghij	Board Member	Former CEO, Canndoc

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Sep. 01, 2021	Listing	NASDAQ GM	abCDe	abCDe
Apr. 23, 2021	IPO	TSX	abCDe	abCDe	07/2023: Delisted from TSX

	FINANCIAL ROUNDS

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Dec. 22, 2024

abCDe

Raised NIS 36m in an Equity Investment. The company also issued warrants, which may further increase the proceeds from the Private Placement up to a total of approximately NIS 77m (approximately $21.5m). In addition, the company received a binding commitment from one of the leading banks in Israel, to provide it with a loan of NIS 30m ($8.3m), for a period of up to 24 months. A total of NIS 66m ($18.2m)raised now, which may increase to NIS 107m ($29.8m).

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Private Investor	abCDe
abC Defghij	Private Investor	abCDe

PIPE

Apr. 23, 2021

abCDe

Investment in Fund

Oct. 31, 2018

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Angel Club/ Group	abCDe
abC Defghij	N/A	abCDe
abC Defghij	N/A	abCDe
abC Defghij	N/A	abCDe

Other

Sep. 27, 2016

abCDe

	Acquisitions made by InterCure (Canndoc)

Acquired Company	Sector	Date	Amount	Remarks
abC Defghij	Agrite...	Sep. 19, 2025	abCDe	Two-phase acquisition, with 50% of the equity acquired at the initial closing. The remaining 50% will be acquired upon achieving 3 months of positive profitability, or after 24 months from the initial closing.
abC Defghij	Agrite...	Feb. 16, 2022	abCDe	Purchase price paid with InterCure shares at the valuation of USD 10 per share
abC Defghij	N/A	Feb. 11, 2019	abCDe	NIS 11.4m

Investment Data

Preferences

Type of Financing

Equity

SECTOR SEGMENTATION (By Number Of Companies)

Biomed

100%

	PORTFOLIO COMPANIES

Current Portfolio Companies (1)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

Fore Biotherapeutics

Fore is a registration stage targeted oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor rationally designed with a first-in-class mechanism to address treatment gaps from 1st and 2nd generation BRAF inhibitors. Plixorafenib has demonstrated single-agent efficacy signals across a variety of tumor types with a manageable safety profile in a Phase 1/2a clinical trial of over 100 patients and is currently enrolling patients in FORTE, a global registrational basket trial to support three distinct indications.

Biomed

Fourth Round	23/08/2023	N/A	$75m
Third Round	21/09/2020	N/A	$57m
First Round	23/12/2015	$2.5m	$10m	Holds 9.3% of the company.

Exits (1)

Company Name		Exit Type	Date Announced	Amount	Remarks
abC Defghij (Other)		Acquired	11/02/2019	abCDe	NIS 11.4m

Historic Portfolio (2)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

CaVnox

Ceased to Operate

Biomed

Seed - Extended

11/07/2022

$0.3m

N/A

Originally a convertible loan from October 2021, converted to shares

Regenera

Ceased to Operate

Biomed

First Round

22/04/2015

$2.5m

$6.5m

Held 17% of the company. 09/2016: Intercure received additional 4% of the company's shares in a share swap deal with BM holdings. 06/2019: Sold 1.4% of the company's shares for $1.3m, now holds 12% of the company.

Last Updated:	abCDe
IVC Number:	abCDe